Clinical Trial Update: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of olaparib, durvalumab, and tremelimumab in patients with BRCA1/BRCA2-mutated recurrent or refractory ovarian, fallopi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Lynparza (olaparib)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: BRCA1 Gene Mutation, BRCA2 Gene Mutation | Phase 2 | Status: COMPLETED | Results posted: 2022-10-05